Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHR-160 spray for hospitalized adults with COVID-19
IRCT20200411047029N1Phase 3Completed
- Sponsor
- Tamasrar Research Institute
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing PHR-160 spray + national standard treatment with Placebo spray + national standard treatment (2 arms). Primary endpoints: Duration of cough, Severity of cough and 7 more. Started Apr 2021; status: completed.
02
Drugs
PHR 160
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200411047029N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200411047029N1.